BLAINJECTIONINJECTABLEPriority Review
Approved
Nov 2015
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
21
Data completeness
6/8 — Strong
Priority Review
EMPLICITI (elotuzumab) by Bristol Myers Squibb is slamf7-directed antibody interactions [moa]. Approved for slamf7-directed immunostimulatory antibody [epc]. First approved in 2015.
Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EMPLICITI (elotuzumab) is a SLAMF7-directed immunostimulatory monoclonal antibody approved in November 2015 for multiple myeloma. It works by engaging immune cells to target myeloma plasma cells through a novel mechanism of action. The drug is administered via intravenous injection in combination with standard therapies.
$0.002BPart D
PeakProduct is in peak commercial phase with modest Part D utilization (203 claims in 2023), suggesting a stable but niche market position requiring specialized oncology expertise.
Mechanism of Action
SLAMF7-directed Antibody Interactions
Pharmacologic Class:
SLAMF7-directed Immunostimulatory Antibody
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (21)
Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM
Started Nov 2024
49 enrolled
MyelomaMultiple MyelomaRefractory Multiple Myeloma
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
Started Jan 2024
795 enrolled
Multiple Myeloma
A Study to Evaluate the Safety of Empliciti® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan
Started Dec 2023
7 enrolled
Relapsed or Refractory Multiple Myeloma
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
Started Sep 2023
410 enrolled
Relapsed Refractory Multiple Myeloma (RRMM)
A Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for Relapsed/Refractory Multiple Myeloma
Started Feb 2023
7 enrolled
Multiple Myeloma
Worked on EMPLICITI at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.